MCID: CRN036
MIFTS: 63

Craniopharyngioma

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Endocrine diseases

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma 12 49 55 51 41 14 69
Dysodontogenic Epithelial Tumor 49
Craniopharyngeal Duct Tumor 49
Neoplasm of Rathke's Pouch 12
Adamantinomatous Tumor 49
Rathke's Pouch Tumor 49

Characteristics:

Orphanet epidemiological data:

55
craniopharyngioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages;

Classifications:



Summaries for Craniopharyngioma

NIH Rare Diseases : 49 Craniopharyngioma is a slow-growing benign (not cancerous) brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). This tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. Although craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, and hearing loss. The cause of these tumors is not well understood; however, researchers suspect that they begin to form during the early stages of embryo development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells). Treatment for craniopharyngioma varies and may include: surgery to remove the tumor, radiation therapy, chemotherapy, and biologic therapy.  Last updated: 3/31/2017

MalaCards based summary : Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to papillary craniopharyngioma and growth hormone deficiency, and has symptoms including abnormal hypothalamus morphology, cerebral calcification and intracranial cystic lesion. An important gene associated with Craniopharyngioma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Glioblastoma Multiforme and Cytoskeleton remodeling Neurofilaments. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and hypothalamus, and related phenotypes are Increased Nanog expression and Increased Nanog expression

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 papillary craniopharyngioma 33.9 BRAF CTNNB1 KRT7
2 growth hormone deficiency 29.7 GHRL IGF1 PROP1
3 adenoma 29.7 BRAF CTNNB1 IGF1 KRT7 PRL
4 pituitary adenoma 29.5 IGF1 POU1F1 PRL TRH
5 ameloblastoma 29.5 KRT14 KRT8 MMP20
6 galactorrhea 29.4 IGF1 PRL
7 insulin-like growth factor i 29.2 IGF1 INS PRL
8 hypogonadotropism 29.1 GNRH1 PRL
9 prader-willi syndrome 29.1 GHRL GNRH1 IGF1 INS
10 bulimia nervosa 2 29.1 GHRL IGF1 PRL
11 pituitary hormone deficiency, combined, 2 29.1 IGF1 POU1F1 PRL PROP1
12 pituitary adenoma, prolactin-secreting 29.0 IGF1 PRL TRH
13 pituitary tumors 28.9 IGF1 POU1F1 PRL PROP1
14 amenorrhea 28.8 GNRH1 PRL TRH
15 chromophobe adenoma 28.7 GNRH1 INS PRL TRH
16 hyperthyroidism 28.6 GHRL INS PRL TRH
17 acromegaly 28.3 GHRL IGF1 INS PRL TRH
18 hypopituitarism 28.1 GNRH1 IGF1 INS POU1F1 PRL PROP1
19 pituitary gland disease 27.9 GNRH1 IGF1 INS POU1F1 PRL PROP1
20 adamantinous craniopharyngioma 12.1
21 cystadenoma 10.9
22 proliferating trichilemmal cyst 10.6 KRT7 KRT8
23 lung acinar adenocarcinoma 10.5 CTNNB1 KRT7
24 endolymphatic sac tumor 10.5 KRT7 KRT8
25 benign breast adenomyoepithelioma 10.5 KRT14 KRT7
26 cutaneous adenocystic carcinoma 10.5 KRT7 KRT8
27 large intestine adenocarcinoma 10.5 CTNNB1 KRT7
28 female reproductive endometrioid cancer 10.5 CTNNB1 KRT7
29 hidrocystoma 10.5 KRT7 KRT8
30 spitz nevus 10.5 BRAF MKI67
31 prostate squamous cell carcinoma 10.5 KRT7 KRT8
32 large cell acanthoma 10.4 KRT14 KRT7
33 hair follicle neoplasm 10.4 CTNNB1 KRT14
34 oncocytic breast carcinoma 10.4 KRT14 KRT7
35 apocrine sweat gland neoplasm 10.4 KRT14 KRT7 KRT8
36 brooke-spiegler syndrome 10.4 KRT14 KRT7 KRT8
37 basaloid squamous cell carcinoma 10.4 KRT14 KRT7 KRT8
38 colorectal adenocarcinoma 10.4 BRAF CTNNB1 KRT7
39 mammary paget's disease 10.4 KRT14 KRT7 KRT8
40 intraneural perineurioma 10.4 KRT14 KRT7 KRT8
41 sweat gland cancer 10.4 KRT14 KRT7 KRT8
42 primary cutaneous amyloidosis 10.4 KRT14 KRT7 KRT8
43 secondary adrenal insufficiency 10.4 IGF1 INS
44 sarcoma, synovial 10.4 CTNNB1 KRT7 KRT8
45 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 IGF1 INS
46 cervical squamous cell carcinoma 10.4 CTNNB1 KRT8 MKI67
47 bladder adenocarcinoma 10.3 KRT7 MKI67
48 nasal cavity cancer 10.3 KRT7 KRT8
49 ameloblastic carcinoma 10.3 KRT14 MKI67
50 endometrial adenocarcinoma 10.3 CTNNB1 KRT7 MKI67

Graphical network of the top 20 diseases related to Craniopharyngioma:



Diseases related to Craniopharyngioma

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

55 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal hypothalamus morphology 55 31 obligate (100%) Obligate (100%) HP:0012286
2 cerebral calcification 55 31 hallmark (90%) Very frequent (99-80%) HP:0002514
3 intracranial cystic lesion 55 31 hallmark (90%) Very frequent (99-80%) HP:0010576
4 neoplasm of the anterior pituitary 55 31 hallmark (90%) Very frequent (99-80%) HP:0011750
5 enlarged pituitary gland 55 31 hallmark (90%) Very frequent (99-80%) HP:0012505
6 central diabetes insipidus 55 31 frequent (33%) Frequent (79-30%) HP:0000863
7 prolactin excess 55 31 frequent (33%) Frequent (79-30%) HP:0000870
8 papilledema 55 31 frequent (33%) Frequent (79-30%) HP:0001085
9 excessive daytime somnolence 55 31 frequent (33%) Frequent (79-30%) HP:0001262
10 obesity 55 31 frequent (33%) Frequent (79-30%) HP:0001513
11 nausea and vomiting 55 31 frequent (33%) Frequent (79-30%) HP:0002017
12 headache 55 31 frequent (33%) Frequent (79-30%) HP:0002315
13 slow decrease in visual acuity 55 31 frequent (33%) Frequent (79-30%) HP:0007924
14 progressive visual field defects 55 31 frequent (33%) Frequent (79-30%) HP:0007987
15 pituitary hypothyroidism 55 31 frequent (33%) Frequent (79-30%) HP:0008245
16 central adrenal insufficiency 55 31 frequent (33%) Frequent (79-30%) HP:0011734
17 bitemporal hemianopia 55 31 frequent (33%) Frequent (79-30%) HP:0030521
18 abnormal visual field test 55 31 frequent (33%) Frequent (79-30%) HP:0030588
19 hydrocephalus 55 31 occasional (7.5%) Occasional (29-5%) HP:0000238
20 hearing impairment 55 31 occasional (7.5%) Occasional (29-5%) HP:0000365
21 optic atrophy 55 31 occasional (7.5%) Occasional (29-5%) HP:0000648
22 delayed puberty 55 31 occasional (7.5%) Occasional (29-5%) HP:0000823
23 increased intracranial pressure 55 31 occasional (7.5%) Occasional (29-5%) HP:0002516
24 polyphagia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002591
25 cerebral ischemia 55 31 occasional (7.5%) Occasional (29-5%) HP:0002637
26 increased susceptibility to fractures 55 31 occasional (7.5%) Occasional (29-5%) HP:0002659
27 proportionate short stature 55 31 occasional (7.5%) Occasional (29-5%) HP:0003508
28 type ii diabetes mellitus 55 31 occasional (7.5%) Occasional (29-5%) HP:0005978
29 sleep apnea 55 31 occasional (7.5%) Occasional (29-5%) HP:0010535
30 sudden loss of visual acuity 55 31 very rare (1%) Very rare (<4-1%) HP:0001117
31 intellectual disability 55 31 very rare (1%) Very rare (<4-1%) HP:0001249
32 seizures 55 31 very rare (1%) Very rare (<4-1%) HP:0001250
33 coma 55 31 very rare (1%) Very rare (<4-1%) HP:0001259
34 global developmental delay 55 31 very rare (1%) Very rare (<4-1%) HP:0001263
35 myocardial infarction 55 31 very rare (1%) Very rare (<4-1%) HP:0001658
36 vertigo 55 31 very rare (1%) Very rare (<4-1%) HP:0002321
37 recurrent infections 55 31 very rare (1%) Very rare (<4-1%) HP:0002719
38 postnatal growth retardation 55 31 very rare (1%) Very rare (<4-1%) HP:0008897
39 abnormality of the nasal bone 55 31 very rare (1%) Very rare (<4-1%) HP:0010939
40 abnormality of the frontal bone 55 31 very rare (1%) Very rare (<4-1%) HP:0430000
41 hypopituitarism 55 Very frequent (99-80%)
42 hypogonadism 55 Frequent (79-30%)
43 sleep disturbance 55 Frequent (79-30%)
44 low gonadotropins (secondary hypogonadism) 55 Frequent (79-30%)
45 growth delay 55 Occasional (29-5%)
46 behavioral abnormality 55 Very rare (<4-1%)
47 hypogonadotrophic hypogonadism 31 frequent (33%) HP:0000044

UMLS symptoms related to Craniopharyngioma:


visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.17 MCM6 MKI67 PROP1 SP7
2 Increased Nanog expression GR00371-A-3 9.17 MCM6 PROP1
3 Increased Nanog expression GR00371-A-5 9.17 PROP1

MGI Mouse Phenotypes related to Craniopharyngioma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.15 KRT8 GNRH1 MCM6 IGF1 BRAF INS
2 endocrine/exocrine gland MP:0005379 10.14 GHRL GNRH1 IGF1 BRAF INS CTNNB1
3 homeostasis/metabolism MP:0005376 10.1 GHRL KRT7 KRT8 GNRH1 IGF1 BRAF
4 digestive/alimentary MP:0005381 9.98 KRT14 GHRL KRT8 GNRH1 BRAF INS
5 hearing/vestibular/ear MP:0005377 9.8 KRT14 KRT8 IGF1 BRAF CTNNB1 POU1F1
6 neoplasm MP:0002006 9.7 KRT14 GNRH1 MCM6 IGF1 BRAF CTNNB1
7 normal MP:0002873 9.56 CTNNB1 GHRL GNRH1 MKI67 IGF1 BRAF
8 reproductive system MP:0005389 9.32 KRT8 GNRH1 IGF1 BRAF INS CTNNB1

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
4 Anesthetics Phase 4,Phase 3
5 Anti-Inflammatory Agents Phase 4,Phase 1
6 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
7 Cortisol succinate Phase 4
8 glucocorticoids Phase 4,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hydrocortisone 17-butyrate 21-propionate Phase 4
13 Hydrocortisone acetate Phase 4
14 Hydrocortisone-17-butyrate Phase 4
15
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
16
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
18
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
19
Ondansetron Approved Phase 3 99614-02-5 4595
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
22
Exenatide Approved, Investigational Phase 3,Phase 2,Phase 1 141758-74-9 15991534
23 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
24 Liver Extracts Phase 3,Phase 1,Phase 2
25 Antihypertensive Agents Phase 3,Phase 2
26 Vasodilator Agents Phase 3,Phase 2
27 Antiemetics Phase 3,Phase 1
28 Autonomic Agents Phase 3,Phase 1
29 BB 1101 Phase 3,Phase 1
30 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
31 Emetics Phase 3
32 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 3,Phase 1
34 Adjuvants, Anesthesia Phase 3
35 Analgesics Phase 3
36 Analgesics, Opioid Phase 3
37 Anesthetics, General Phase 3
38 Anesthetics, Intravenous Phase 3
39 Central Nervous System Depressants Phase 3,Phase 1
40 Narcotics Phase 3
41 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
42 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
43 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
44 Nootropic Agents Phase 3,Phase 2,Early Phase 1
45 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
46 Incretins Phase 3,Phase 2,Phase 1
47 glucagon Phase 3
48 Glucagon-Like Peptide 1 Phase 3
49 Cola Nutraceutical Phase 3,Phase 1
50
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 105)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
4 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
5 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
7 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Recruiting NCT02860923 Phase 3 Exenatide;Placebo
8 Energy Balance & Weight Loss in Craniopharyngioma-related Hypothalamic Obesity Recruiting NCT02664441 Phase 3 Exenatide;placebo
9 90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors Recruiting NCT02081768 Phase 3
10 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
11 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
12 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
13 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
14 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
15 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
16 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
17 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
18 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
19 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
20 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
21 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
22 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
23 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
24 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
25 Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib
26 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
27 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
28 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
29 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Active, not recruiting NCT01964300 Phase 2
30 Effects of Exenatide on Hypothalamic Obesity Active, not recruiting NCT01061775 Phase 1, Phase 2 Exenatide
31 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
32 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
33 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
34 Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy Terminated NCT01348607 Phase 2 methylphenidate hydrochloride;modafinil;placebo
35 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156 Phase 1
36 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
37 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
38 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
39 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
40 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
41 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
42 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
43 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
44 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
45 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
46 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
47 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
48 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
49 O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
50 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Genetic Tests for Craniopharyngioma

Anatomical Context for Craniopharyngioma

MalaCards organs/tissues related to Craniopharyngioma:

38
Brain, Pituitary, Hypothalamus, Bone, Testes, Spinal Cord, T Cells

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 775)
# Title Authors Year
1
Abscess inside craniopharyngioma: diagnostic and management implications. ( 29431099 )
2018
2
Craniopharyngioma - a chronic disease. ( 29442345 )
2018
3
The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study. ( 29388032 )
2018
4
Long-term visual outcomes of craniopharyngioma in children. ( 29344823 )
2018
5
Combined endoscopic approach in the management of suprasellar craniopharyngioma. ( 29435609 )
2018
6
The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort. ( 29314661 )
2018
7
Extended Endoscopic Endonasal Approach for Craniopharyngioma Removal. ( 29404250 )
2018
8
Limits of endoscopic endonasal surgery for craniopharyngioma. ( 29378389 )
2018
9
In Reply to the Letter to the Editor Regarding "Anatomic Dissection of Arachnoid Membranes Encircling the Pituitary Stalk on Fresh Non-Formalin-Fixed Specimens: Anatomoradiologic Correlations and Clinical Applications in Craniopharyngioma Surgery". ( 29232814 )
2018
10
Extended Endoscopic Endonasal Approach for Suprasellar Craniopharyngioma. ( 29404249 )
2018
11
The Posterior Transpetrosal Approach in a Case of Large Retrochiasmatic Craniopharyngioma: Operative Video and Technical Nuances. ( 29404253 )
2018
12
Endoscopic Transsphenoidal Resection of Craniopharyngioma. ( 29404252 )
2018
13
Micturition Disorders as the First Symptom of Multiple Pituitary Hormone Deficiency Caused by Craniopharyngioma. ( 29314378 )
2018
14
Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma with Fascia Lata Button and Nasoseptal Flap Reconstruction. ( 29404247 )
2018
15
Letter to the Editor Regarding "Anatomic Dissection of Arachnoid Membranes Encircling the Pituitary Stalk on Fresh Non-Formalin-Fixed Specimens: Anatomoradiologic Correlations and Clinical Applications in Craniopharyngioma Surgery". ( 29232813 )
2018
16
Expanded Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma. ( 29404248 )
2018
17
Anorexia-cachexia syndrome-like hypothalamic neuroendocrine dysfunction in a patient with a papillary craniopharyngioma. ( 28469924 )
2017
18
Sphenoid wing en plaque meningioma development following craniopharyngioma surgery and radiotherapy: Radiation-induced after three decades. ( 28761508 )
2017
19
Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology. ( 28414891 )
2017
20
MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. ( 28506993 )
2017
21
Predictors of visual outcome in patients operated for craniopharyngioma - a Danish national study. ( 28661562 )
2017
22
Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. ( 28918496 )
2017
23
Microstructure alterations in the Hypothalamus in cranially radiated Childhood Leukemia survivors but not in Craniopharyngioma patients unaffected by hypothalamic damage. ( 28502079 )
2017
24
Norman M. Dott, master of hypothalamic craniopharyngioma surgery: the decisive mentoring of Harvey Cushing and Percival Bailey at Peter Bent Brigham Hospital. ( 28059655 )
2017
25
In Reply to "Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement". ( 28732411 )
2017
26
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. ( 28481062 )
2017
27
Recovery from diabetes insipidus and preservation of thyroid function after craniopharyngioma removal and pituitary stalk sectioning. ( 28917091 )
2017
28
Primary Ectopic Ethmoidal Craniopharyngioma. ( 28403130 )
2017
29
Do craniopharyngioma molecular signatures correlate with clinical characteristics? ( 28707994 )
2017
30
Recent advances in molecular pathology of craniopharyngioma. ( 28781761 )
2017
31
Multi-modality, Multi-directional Resection of Craniopharyngioma: versatility in alternating the principal and auxiliary surgical corridors and visualization modalities. ( 28344177 )
2017
32
Psychological well-being and independent living of young adults with childhood-onset craniopharyngioma. ( 28485516 )
2017
33
Adult Craniopharyngioma: Case Series, Systematic Review, and Meta-Analysis. ( 29267973 )
2017
34
Effect of Preserving the Pituitary Stalk During Resection of Craniopharyngioma in Children on the Diabetes Insipidus and Relapse Rates and Long-Term Outcomes. ( 28749844 )
2017
35
Endocrine Disorders Developing after Surgical Intervention of Craniopharyngioma in Children. ( 28508600 )
2017
36
Child dermoid cyst mimicking a craniopharyngioma: the benefit of MRI T2-weighted diffusion sequence. ( 28921047 )
2017
37
The neuroendocrine sequelae of paediatric craniopharyngioma: a 40 year meta-data analysis of 185 cases from three UK centres. ( 28073908 )
2017
38
Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. ( 28069929 )
2017
39
A Rare Case of Craniopharyngioma in the Temporal Lobe. ( 29441211 )
2017
40
Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply. ( 28922866 )
2017
41
Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. ( 28455541 )
2017
42
Spontaneous intraventricular rupture of a craniopharyngioma cyst: A case report. ( 28660168 )
2017
43
The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. ( 28882980 )
2017
44
Craniopharyngioma: Surgical Outcome as Related to the Degree of Hypothalamic Involvement. ( 28732410 )
2017
45
Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. ( 28499018 )
2017
46
Proteomics in pediatric cystic craniopharyngioma. ( 28414889 )
2017
47
Papillary craniopharyngioma: A clinicopathologic study of a rare entity from a major tertiary care center in Pakistan. ( 28488624 )
2017
48
Intracystic interferon-alpha in pediatric craniopharyngioma patients. ( 28922862 )
2017
49
Malignant Transformation of Craniopharyngioma without Radiation Therapy: Case Report and Review of the Literature. ( 28061501 )
2017
50
Hypothalamic involvement in craniopharyngioma-Implications for surgical, radiooncological, and molecularly targeted treatment strategies. ( 29286573 )
2017

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
2 CTNNB1 NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103
3 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103

Cosmic variations for Craniopharyngioma:

9 (show all 22)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5676 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>T p.T41I 6
2 COSM5669 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>T p.S33F 6
3 COSM5673 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>A p.S33Y 6
4 COSM5662 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>T p.S37F 6
5 COSM5687 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.109T>C p.S37P 6
6 COSM5677 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>G p.S33C 6
7 COSM5668 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>C p.D32H 6
8 COSM5679 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>G p.S37C 6
9 COSM5672 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>A p.D32N 6
10 COSM5683 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>G p.S33A 6
11 COSM5682 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>C p.S33P 6
12 COSM5686 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>A p.G34R 6
13 COSM5684 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>C p.G34R 6
14 COSM5661 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>T p.D32Y 6
15 COSM5674 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.104T>G p.I35S 6
16 COSM5691 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>T p.D32V 6
17 COSM5681 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>G p.D32G 6
18 COSM5663 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.133T>C p.S45P 6
19 COSM5664 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.121A>G p.T41A 6
20 COSM5701 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>G p.T41S 6
21 COSM5758 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.127G>A p.A43T 6
22 COSM476 BRAF pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.1799T>A p.V600E 6

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Pathways for Craniopharyngioma

GO Terms for Craniopharyngioma

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 9.16 INS PRL
2 keratin filament GO:0045095 9.13 KRT14 KRT7 KRT8
3 cell periphery GO:0071944 8.8 CTNNB1 KRT14 KRT8

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.72 BRAF GHRL GNRH1 IGF1 PROP1
2 cornification GO:0070268 9.65 KRT14 KRT7 KRT8
3 negative regulation of angiogenesis GO:0016525 9.58 CTNNB1 GHRL PRL
4 positive regulation of MAPK cascade GO:0043410 9.54 CTNNB1 IGF1 INS
5 positive regulation of glycolytic process GO:0045821 9.49 IGF1 INS
6 cell fate specification GO:0001708 9.46 CTNNB1 POU1F1
7 positive regulation of glycogen biosynthetic process GO:0045725 9.43 IGF1 INS
8 adenohypophysis development GO:0021984 9.26 POU1F1 PROP1
9 negative regulation of feeding behavior GO:2000252 9.16 INS TRH
10 regulation of receptor activity GO:0010469 9.1 GHRL GNRH1 IGF1 INS PRL TRH
11 somatotropin secreting cell differentiation GO:0060126 8.96 POU1F1 PROP1

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GHRL GNRH1 IGF1 INS PRL TRH
2 insulin-like growth factor receptor binding GO:0005159 8.96 IGF1 INS

Sources for Craniopharyngioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....